CEACAM5 and lung carcinoma: sPLA2-IIa is the best biomarker relative to Cyfra 21.1 and CEA, and the combined sPLA2-IIa, Cyfra 21.1 and CEA tests increase the sensitivity for lung cancer prediction relative to sPLA2-IIa test alone.